TY - JOUR T1 - Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma JF - bioRxiv DO - 10.1101/049072 SP - 049072 AU - Chandler D. Gatenbee AU - NĂºria Folguera-Blasco AU - Charlie Daneils AU - Jill Gallaher AU - Russ Rockne AU - Michael Nicholson AU - Eleni Maniati AU - John Kennedy AU - Kimberly Luddy AU - Frederick L. Locke AU - Mark Robertson-Tessi Y1 - 2016/01/01 UR - http://biorxiv.org/content/early/2016/04/18/049072.abstract N2 - Standard of care for multiple myeloma involves autologous hematopoietic cell transplant (AHCT), which can extend life by a year; however the disease remains incurable. A dendritic cell vaccine developed at Moffitt will be used both immediately before and after AHCT, with the aim of achieving complete response. Data will be collected during the trial to test the biological activity of the vaccine. This data will parameterize a model that facilitates the exploration of outcomes when varying the timing of vaccination. This calibrated model will also inform the design of a follow-up trial, which will include vaccination in conjunction with other immunotherapies. ER -